TruScreen Group (TRU) AGM 2024 Presentation summary
Event summary combining transcript, slides, and related documents.
AGM 2024 Presentation summary
13 Jun, 2025Opening remarks and agenda
CEO Marty Dillon opened the AGM, outlining key achievements for FY2024 and setting the agenda to include financial review, market expansion, technology improvements, cost reduction, and Q&A.
Financial performance review
Sales increased 27% year-over-year, with total revenue reaching NZD $2.6m and SUS sales up 25%.
EBITDA improved by 15% and net assets rose 28% compared to the previous year.
Cash position increased 23% year-over-year, and a NZD $2.6m rights issue and placement was completed in March 2024.
Loss for the year reduced to NZD $2.0m from NZD $2.4m in FY23.
Strategic initiatives and plans
Targeting month-to-month cash flow positivity by 31 March 2025.
Focus on market growth, lowering COGS, and reducing operating costs over the next fiscal year.
China remains the largest market and top priority, with plans to increase device installations from 97 to 150 and SUS pull-through from 129 to 290 per device per month.
Expansion efforts underway in Vietnam, Mexico, Eastern Europe, Central Asia, Africa, and the Middle East, with tailored objectives for each region.
Technology improvements include enhancing Single Use Sensor production, device self-calibration, and reducing head office costs.
Latest events from TruScreen Group
- FY26 growth is driven by public program expansion, new markets, and product diversification.TRU
AGM 20259 Jul 2026 - Revenue down 17% to NZ$860k; capital raised and public programs set to drive 2H growth.TRU
H1 20268 Jul 2026 - FY2025 sales fell on rollout delays, but FY2026 is set for strong growth with new markets and alliances.TRU
H2 202517 Jun 2026 - Sales up 42% YOY, gross margin 31.5%, and $4m raised to fund global expansion.TRU
H2 202617 Jun 2026 - Sales up 5% year-over-year, with narrowed operating loss and expanding global adoption.TRU
H1 202516 Jun 2026 - AI-driven cervical cancer screening device posts rapid sales growth and global expansion.TRU
Investor presentation20 May 2026 - AI-driven cervical cancer screening sales up 27% YOY, led by China and LMIC expansion.TRU
Investor presentation15 May 2026 - FY26 sales projected to surpass NZ$2.8m as public programs and new markets accelerate growth.TRU
Investor presentation15 May 2026